1. 2341 Tumor genotyping and clonal evolution in KIT during regorafenib treatment in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST. (September 2015) Authors: Jeffers, M.; Beckmann, G.; Reischl, J.; Rutstein, M.; Wagner, A.; Demetri, G.D.; Teufel, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Lenz, G.; Hawkes, E.; Verhoef, G.; Haioun, C.; Lim, S.; Heo, D.; Ardeshna, K.; Chong, G.; Christensen, J.H.; Shi, V.; Lippert, S.; Hiemeyer, F.; Piraino, P.; Beckmann, G.; Peña, C.; Buvaylo, V.; Childs, B.H.; Gorbatchevsky, I.; Salles, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗